| Public | PINK:CRXLY |
| Date | 3/11 |
| Acquired by | Johnson & Johnson |
| Price | $2.3B |
| Date | 2/11 |
| Terms | Cash |
| Website | crucell.com |
| Category | BioTech |
| Phone | 31(0)-71-519-91-00 |
| info@crucell.com | |
| Employees | |
| Founded | 1993 |
| Description | Pharmaceutical Development |
| TOTAL | $443M |
| FUNDING TOTAL | $443M |
| Venture Round, 9/09 Johnson & Johnson | $443M |
Crucell N.V. is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market.
